|
US6307025B1
(en)
|
1989-04-28 |
2001-10-23 |
Biogen, Inc. |
VCAM fusion proteins and DNA coding therefor
|
|
US5871734A
(en)
*
|
1992-01-13 |
1999-02-16 |
Biogen, Inc. |
Treatment for asthma with VLA-4 blocking agents
|
|
US5932214A
(en)
*
|
1994-08-11 |
1999-08-03 |
Biogen, Inc. |
Treatment for inflammatory bowel disease with VLA-4 blockers
|
|
DK0678122T3
(da)
|
1993-01-12 |
2000-03-06 |
Biogen Inc |
Rekombinante anti-VLA4 antistofmolekyler
|
|
WO1994017828A2
(en)
*
|
1993-02-09 |
1994-08-18 |
Biogen, Inc. |
Treatment for insulin dependent diabetes
|
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
|
US5840299A
(en)
*
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
US6551593B1
(en)
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
|
US7750137B2
(en)
|
1995-09-01 |
2010-07-06 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressins
|
|
US7803904B2
(en)
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
|
AU7348798A
(en)
*
|
1997-05-09 |
1998-12-08 |
John P. Robarts Research Institute, The |
Method for dislodging infiltrated leukocytes from a tissue
|
|
DE19741235A1
(de)
|
1997-09-18 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
DE19741873A1
(de)
*
|
1997-09-23 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
DE19751251A1
(de)
|
1997-11-19 |
1999-05-20 |
Hoechst Marion Roussel De Gmbh |
Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
|
|
DE19821483A1
(de)
|
1998-05-14 |
1999-11-18 |
Hoechst Marion Roussel De Gmbh |
Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
DK1113810T3
(da)
*
|
1998-09-14 |
2009-04-06 |
Univ Texas |
Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
|
|
US7618630B2
(en)
|
1998-09-14 |
2009-11-17 |
Board Of Regents, The University Of Texas System |
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
|
|
HK1041452B
(en)
|
1999-04-22 |
2005-10-14 |
Biogen Idec Ma Inc. |
Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
|
|
DE19922462A1
(de)
|
1999-05-17 |
2000-11-23 |
Aventis Pharma Gmbh |
Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
CZ300710B6
(cs)
|
1999-06-01 |
2009-07-22 |
Biogen Idec Ma Inc. |
Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
DE60043308D1
(de)
*
|
1999-12-16 |
2009-12-24 |
Biogen Idec Inc |
Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
|
|
DE10111877A1
(de)
|
2001-03-10 |
2002-09-12 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
UA83791C2
(ru)
|
2001-04-13 |
2008-08-26 |
Байоджен Айдек Ма Инк. |
Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
|
|
DE10137595A1
(de)
|
2001-08-01 |
2003-02-13 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
|
|
PL215263B1
(pl)
|
2002-02-25 |
2013-11-29 |
Elan Pharm Inc |
Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
|
|
AU2003226065B2
(en)
*
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
|
GB0210121D0
(en)
*
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
AR040778A1
(es)
*
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
|
|
DK1572748T3
(da)
*
|
2002-12-17 |
2010-08-23 |
Merck Patent Gmbh |
Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
|
|
CU23403A1
(es)
*
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
WO2005061466A1
(ja)
|
2003-12-22 |
2005-07-07 |
Ajinomoto Co., Inc. |
新規フェニルアラニン誘導体
|
|
JP2008520717A
(ja)
*
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
|
AU2006316629A1
(en)
*
|
2005-11-17 |
2007-05-31 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
|
|
US10119979B2
(en)
|
2006-05-25 |
2018-11-06 |
Biogen Ma Inc. |
Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
|
|
US20100150915A1
(en)
|
2007-02-20 |
2010-06-17 |
Stewart Edward J |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
|
AU2008266051B2
(en)
|
2007-06-14 |
2014-07-31 |
Biogen Ma Inc. |
Antibody formulations
|
|
WO2009075388A1
(ja)
|
2007-12-13 |
2009-06-18 |
Tokuyama Corporation |
フォトクロミック硬化性組成物
|
|
MX2010011145A
(es)
|
2008-04-11 |
2011-04-11 |
Merrimack Pharmaceuticals Inc |
Enlazadores de la albumina de suero humana y conjugados de la misma.
|
|
KR101391472B1
(ko)
|
2009-03-20 |
2014-05-07 |
암젠 인크 |
알파-4-베타-7 이종이량체 특이적 길항제 항체
|
|
WO2011020874A1
(en)
|
2009-08-20 |
2011-02-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
|
PT2558499T
(pt)
|
2010-04-16 |
2017-07-14 |
Biogen Ma Inc |
Anticorpos anti-vla-4
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
KR101875155B1
(ko)
|
2011-05-02 |
2018-07-09 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항-α4β7 항체에 대한 제형
|
|
NZ629204A
(en)
|
2012-02-16 |
2016-09-30 |
Santarus Inc |
Anti-vla1 (cd49a) antibody pharmaceutical compositions
|
|
WO2018002036A1
(en)
|
2016-06-28 |
2018-01-04 |
Zaklady Farmaceutyczne Polpharma Sa |
Recombinant production of monoclonal antibodies
|
|
WO2018091729A2
(en)
|
2016-11-21 |
2018-05-24 |
Zaklady Farmaceutyczne Polpharma Sa |
Aqueous pharmaceutical formulations
|
|
EP4659808A2
(en)
*
|
2017-02-17 |
2025-12-10 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
WO2018224673A1
(en)
|
2017-06-08 |
2018-12-13 |
Zaklady Farmaceutyczne Polpharma S.A. |
Improved methods of cell culture
|
|
US12037398B2
(en)
|
2018-06-04 |
2024-07-16 |
Biogen Ma Inc. |
Anti-VLA-4 antibodies having reduced effector function
|
|
US20240301512A1
(en)
|
2021-01-29 |
2024-09-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
|